Please Wait
Applying Filters...
menu
    • menu
    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-27

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Romosozumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 13Evenity

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    U.S.A
    arrow
    IMCAS World Congress
    Not Confirmed

    Amgen

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 350

    2019 Revenue in Millions : 189

    Growth (%) : 85

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Japan
    arrow
    IMCAS World Congress
    Not Confirmed

    Astellas

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 240

    2019 Revenue in Millions : 157

    Growth (%) : 53

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Evenity

    Romosozumab

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Belgium
    arrow
    IMCAS World Congress
    Not Confirmed

    UCB

    Romosozumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2020 Revenue in Millions : 2

    2019 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    U.S.A
    arrow
    IMCAS World Congress
    Not Confirmed

    Amgen

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 530

    2020 Revenue in Millions : 350

    Growth (%) : 51

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Japan
    arrow
    IMCAS World Congress
    Not Confirmed

    Astellas

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 246

    2020 Revenue in Millions : 238

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Evenity

    Romosozumab

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Belgium
    arrow
    IMCAS World Congress
    Not Confirmed

    UCB

    Romosozumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2021 Revenue in Millions : 11

    2020 Revenue in Millions : 2

    Growth (%) : 400

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    U.S.A
    arrow
    IMCAS World Congress
    Not Confirmed

    Amgen

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2022 Revenue in Millions : 787

    2021 Revenue in Millions : 530

    Growth (%) : 48

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Japan
    arrow
    IMCAS World Congress
    Not Confirmed

    Astellas

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2022 Revenue in Millions : 302

    2021 Revenue in Millions : 265

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Evenity

    Romosozumab

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    Belgium
    arrow
    IMCAS World Congress
    Not Confirmed

    UCB

    Romosozumab

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2022 Revenue in Millions : 27

    2021 Revenue in Millions : 11

    Growth (%) : 142

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Evenity

    Romosozumab-aqqg

    arrow
    IMCAS World Congress
    Not Confirmed

    Brand Name : Evenity

    U.S.A
    arrow
    IMCAS World Congress
    Not Confirmed

    Amgen

    Romosozumab-aqqg

    Main Therapeutic Indication : Musculoskeletal

    Currency : USD

    2023 Revenue in Millions : 1,160

    2022 Revenue in Millions : 787

    Growth (%) : 47

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF